Cellectis (NASDAQ:CLLS) Upgraded by StockNews.com to "Buy" Rating

StockNews.com upgraded shares of Cellectis (NASDAQ:CLLS - Free Report) from a hold rating to a buy rating in a report published on Monday.

Cellectis Stock Down 5.8 %

Shares of NASDAQ CLLS traded down $0.07 on Monday, hitting $1.13. The company had a trading volume of 94,231 shares, compared to its average volume of 140,983. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.48. Cellectis has a 12-month low of $1.11 and a 12-month high of $3.38. The firm has a market capitalization of $62.81 million, a P/E ratio of -0.87 and a beta of 3.21. The business has a 50 day moving average of $1.40 and a two-hundred day moving average of $1.72.

Cellectis (NASDAQ:CLLS - Get Free Report) last released its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of $0.06 by ($0.22). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The company had revenue of $33.22 million during the quarter, compared to analysts' expectations of $5.90 million. As a group, equities research analysts forecast that Cellectis will post -0.46 earnings per share for the current fiscal year.

Institutional Trading of Cellectis

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Wells Fargo & Company MN increased its holdings in shares of Cellectis by 103.4% in the 4th quarter. Wells Fargo & Company MN now owns 24,590 shares of the biotechnology company's stock valued at $44,000 after acquiring an additional 12,500 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Cellectis in the 4th quarter valued at about $962,000. Finally, B Group Inc. bought a new stake in shares of Cellectis during the 4th quarter valued at about $5,547,000. 63.90% of the stock is owned by institutional investors.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.